REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/06/2025
Back to search
Official data from USPTO
BP BALKAN PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
10/07/2025
Trademark type
Combined
Nice classes
5
Filing date
10/01/2019
Registration date
10/06/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/06/2020
Last transaction
10/07/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
RO
Examiner
SEVERSON,JUSTIN
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the letters "BP" with a vertical curved band between the letters, all in blue, to the left of a blue double helix design. Below the letters and design is the wording "BALKAN PHARMACEUTICALS" in blue letters. All on a white background.
Holders and representatives
Holders
EURO MAST INDUSTRIES S.R.L., societate comerciala
Representatives
Bruce S. Londa Norris McLaughlin P.A.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalmedical and veterinary productsproducts for treating digestive maladies and for affecting metabolism namelyantacidsantiulcerous preparationsantiflatulence preparations; antispasticsanticolinergicsantipropulsives; antivomitive and antinauseantsantidiarrheals; digestive aidsfood enzyme and dietary supplements; metabolic aidsstanozololmethandienonemesteroloneoxandrolone and nandrolone; products for treating the liverlipotropics; products for treating disorders and illnesses of bloodhaematopoetic organs- and the heparin groupplatelet antiaggregants; products for treating disorders and illnesses of the cardiovascular system and for providing heart therapydiureticsperipherical vasodilators; blockersbisoprololpantoprazolefamotidine and naltrexone; products that act on the renin-angiotensin systemramiprillizinoprilenalapril and captoprile; pharmaceuticalslipid lowering agents; genital-urinary system and sexual hormonessexual and modulator hormones of the genital systemgenital system medications; systemic hormonal preparations; antiinfectious products for systemic useofloxacinemetronidazoleacycloviramoxaciline and furaciline; antineoplastic agents and immunomodulators; products for treating the skeletal muscle systemantiinflammatory and antirheumatic non-steroids; products for treating the nervous systemanestheticsanticonvulsantsantiemeticsantiparkinson agentsCNS stimulantsmuscle relaxantsnarcotic analgesicsnonnarcotic analgesicssedatives; antiparasitics; products for treating the breathing pathwayantiasthmaticssystemic antihistamines; sanitary products for medical useabsorbent products for personal health care and hygienemedical disinfectant liquidswipessprays and soaps
Publications
History of USPTO decisions and trademark events.
31 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/01/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
01/28/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
01/28/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/06/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
10/06/2020
GPNX
NOTIFICATION PROCESSED BY IB
07/31/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/21/2020
PUBO
PUBLISHED FOR OPPOSITION
07/21/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/15/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/15/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/01/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/17/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/20/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/19/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/19/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/24/2020
GNRT
NON-FINAL ACTION E-MAILED
04/24/2020
CNRT
NON-FINAL ACTION WRITTEN
04/24/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/26/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/26/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/26/2020
RFNT
REFUSAL PROCESSED BY IB
02/22/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/05/2020
RFRR
REFUSAL PROCESSED BY MPU
02/05/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/11/2020
CNRT
NON-FINAL ACTION WRITTEN
01/10/2020
DOCK
ASSIGNED TO EXAMINER
01/03/2020
MAFR
APPLICATION FILING RECEIPT MAILED
12/06/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/02/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/28/2019
Continuous trademark protection
Get notified about every new filing that threatens BP BALKAN PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.